ACROBIOSYSTEMS CO.,LTD. — Investor Relations & Filings
ACROBIOSYSTEMS CO.,LTD. is a global biotechnology company specializing in the development and manufacturing of high-quality recombinant proteins and critical reagents for the life sciences industry. The company provides a comprehensive portfolio of products designed to accelerate the development of target therapeutics, including antibodies, cell and gene therapies, and vaccines. Key offerings include a wide range of biotinylated proteins, enzymes, and assay kits characterized by high bioactivity and batch-to-batch consistency. ACROBIOSYSTEMS supports drug discovery and clinical development through specialized platforms for protein engineering and characterization. Its products serve a diverse client base of pharmaceutical companies, biotechnology firms, and academic research institutions worldwide, focusing on therapeutic areas such as oncology, immunology, and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 第二届董事会第三次会议决议公告 | 2023-09-15 | Chinese | |
| 2023年限制性股票激励计划（草案)摘要 | 2023-09-15 | Chinese | |
| 2023年限制性股票激励计划（草案） | 2023-09-15 | Chinese | |
| 关于召开2023年第二次临时股东大会的通知 | 2023-09-15 | Chinese | |
| 2023年限制性股票激励计划首次授予部分激励对象名单 | 2023-09-15 | Chinese | |
| 关于回购公司股份的进展公告 | 2023-09-04 | Chinese |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2023
15 filings
| |||||
| 44576802 | 第二届董事会第三次会议决议公告 | 2023-09-15 | Chinese | ||
| 44576788 | 2023年限制性股票激励计划（草案)摘要 | 2023-09-15 | Chinese | ||
| 44576779 | 2023年限制性股票激励计划（草案） | 2023-09-15 | Chinese | ||
| 44576768 | 关于召开2023年第二次临时股东大会的通知 | 2023-09-15 | Chinese | ||
| 44576757 | 2023年限制性股票激励计划首次授予部分激励对象名单 | 2023-09-15 | Chinese | ||
| 44576747 | 关于回购公司股份的进展公告 | 2023-09-04 | Chinese | ||
| 44576736 | 招商证券股份有限公司关于北京百普赛斯生物科技股份有限公司2023年半年度跟踪报告 | 2023-09-01 | Chinese | ||
| 44576727 | 关于调整2022年限制性股票激励计划首次及预留授予价格及授予数量的公告 | 2023-08-28 | Chinese | ||
| 44576718 | 深圳市他山企业管理咨询有限公司关于北京百普赛斯生物科技股份有限公司2022年限制性股票激励计划调整及首次授予部分第一个归属期归属条件未成就并作废部分限制性股票事项的独立财务顾问报告 | 2023-08-28 | Chinese | ||
| 44576710 | 独立董事关于第二届董事会第二次会议相关事项的独立意见 | 2023-08-28 | Chinese | ||
| 44576702 | 非经营性资金占用及其他关联资金往来情况汇总表 | 2023-08-28 | Chinese | ||
| 44576695 | 2023年半年度报告 | 2023-08-28 | Chinese | ||
| 44576657 | 关于2022年限制性股票首次授予部分第一个归属期归属条件未成就并作废部分已授予但尚未归属的限制性股票的公告 | 2023-08-28 | Chinese | ||
| 44576647 | 监事会决议公告 | 2023-08-28 | Chinese | ||
| 44576638 | 2023年半年度报告摘要 | 2023-08-28 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ACROBIOSYSTEMS CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56034/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56034 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56034 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56034 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56034}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ACROBIOSYSTEMS CO.,LTD. (id: 56034)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.